<DOC>
	<DOCNO>NCT02821910</DOCNO>
	<brief_summary>The purpose trial demonstrate relative bioavailability 2 newly develop fix dose combination ( FDC ) tablets contain empagliflozin , linagliptin &amp; metformin extend release ( XR ) single tablet empagliflozin , linagliptin metformin XR administer simultaneously .</brief_summary>
	<brief_title>Relative Bioavailability 2 Fixed Dose Combinations Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Healthy male female subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead electrocardiogram , clinical laboratory test Age 18 55 year ( incl . ) BMI 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP local legislation Male subject , female subject meet follow criterion start least 30 day first administration trial medication 30 day trial completion : Use adequate contraception , e.g . follow method plus condom : implant , injectables , combine oral vaginal contraceptive , intrauterine device Sexually abstinent A vasectomised sexual partner ( vasectomy least 1 year prior enrolment ) Surgically sterilise ( include hysterectomy ) Postmenopausal , define least 1 year spontaneous amenorrhea ( questionable case blood sample simultaneous level folliclestimulating hormone 40 U/L estradiol 30 ng/L confirmatory ) Exclusion criterion : Any find medical examination ( include blood pressure , pulse rate electrocardiogram ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 45 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>